BioLineRx
BLRX
BioLineRx (BLRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.00
- EPS estimate
- $0.00
- EPS surprise
- +0.00%
- Revenue surprise
- −41.20%
- Revenue
- $294,000.00
- Revenue estimate
- $500,000.00
- Reported
- Invalid Date
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Invalid Date | $0.00 | $0.00 | +0.00% | $294,000.00 | — |
| Q1 2026 | May 27, 2026 | −$1.04 | $0.00 | +100.00% | $477,000.00 | SEC |
| Q4 2025 | Mar 23, 2026 | −$0.39 | −$0.27 | +29.87% | $514,000.00 | SEC |
| Q3 2025 | Nov 24, 2025 | −$0.67 | $0.00 | +100.00% | $427,000.00 | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.35 | $0.00 | +100.00% | $304,000.00 | SEC |
| Q1 2025 | May 27, 2025 | −$0.95 | $0.00 | +100.00% | $255,000.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.81 | −$1.60 | −98.19% | $11.7M | SEC |
| Q3 2024 | Nov 25, 2024 | −$1.74 | $0.00 | +100.00% | $4.9M | SEC |
| Q2 2024 | Aug 15, 2024 | −$3.02 | $0.00 | +100.00% | $5.4M | SEC |
| Q1 2024 | May 28, 2024 | −$11.66 | $0.00 | +100.00% | $6.9M | SEC |
| Q4 2023 | Mar 26, 2024 | −$8.84 | −$7.64 | +13.64% | $4.8M | SEC |
| Q3 2023 | Nov 20, 2023 | −$8.44 | −$12.00 | −42.15% | $0.00 | SEC |
| Q2 2023 | Aug 30, 2023 | −$6.83 | −$12.00 | −75.59% | $0.00 | SEC |
| Q1 2023 | May 24, 2023 | −$5.63 | −$6.00 | −6.61% | $0.00 | SEC |
| Q4 2022 | Mar 22, 2023 | −$5.43 | −$3.62 | +33.33% | $0.00 | SEC |
| Q3 2022 | Nov 15, 2022 | −$6.63 | −$6.00 | +9.54% | $0.00 | — |
| Q2 2022 | Aug 16, 2022 | −$5.23 | −$6.00 | −14.81% | $0.00 | — |
| Q1 2022 | May 11, 2022 | −$6.03 | −$6.00 | +0.50% | $0.00 | — |
| Q4 2021 | Mar 16, 2022 | −$5.63 | $0.00 | +100.00% | $0.00 | — |
| Q3 2021 | Nov 18, 2021 | −$5.03 | −$6.00 | −19.40% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did BioLineRx (BLRX) last report earnings?
BioLineRx last reported on Invalid Date, covering fiscal Q2 2026.
Did BLRX beat earnings estimates?
BioLineRx reported EPS of $0.00 for Q2 2026, in line with the $0.00 consensus estimate.
How much revenue did BLRX report last quarter?
BioLineRx reported $294,000.00 in revenue for Q2 2026, against a consensus estimate of $500,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.